EMEA Advisers Recommend Approval for Exubera

Drug Industry Daily
KEYWORDS International / risk
A A

Pfizer and sanofi-aventis received more positive news last week on their highly anticipated inhaled insulin drug Exubera when a European Medicines Agency (EMEA) advisory committee recommended approval of the product for Type 1 and 2 diabetes.

To View This Article:

Login

Subscribe To Drug Industry Daily